Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Investigation

• Publication date

  2005-01-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI22477PMID 15630450PMCID PMC539195
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [''R"--project for statistical computing].

  2008cited by this paper
• Acute lymphoblastic leukemia.

  2004cited by this paper
• Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1).

  2004cited by this paper
• A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells.

  2004cited by this paper
• Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis.

  2004cited by this paper
• The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis.

  2003cited by this paper
• Results of therapy for acute lymphoblastic leukemia in black and white children.

  2003cited by this paper
• E2A–PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features

  2003cited by this paper
• The role of breast cancer resistance protein in acute lymphoblastic leukemia.

  2003cited by this paper
• Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.

  2003cited by this paper
• Classification of pediatric acute lymphoblastic leukemia by gene expression profiling.

  2003cited by this paper
• Loss of Multidrug Resistance Protein 1 Expression and Folate Efflux Activity Results in a Highly Concentrative Folate Transport in Human Leukemia Cells*

  2003cited by this paper
• Resistance to antifolates

  2003cited by this paper
• De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.

  2002cited by this paper
• Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.

  2002cited by this paper
• Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.

  2002cited by this paper
• Multiple tests for genetic effects in association studies.

  2002cited by this paper
• The genetics of the E2F family of transcription factors: shared functions and unique roles.

  2002cited by this paper
• The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study

  2001cited by this paper
• Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport.

  2001cited by this paper
• Glutamyl hydrolase. pharmacological role and enzymatic characterization.

  2000cited by this paper
• Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.

  2000cited by this paper
• Purification and Properties of a Folate-catabolizing Enzyme*

  2000cited by this paper
• mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method

  2000cited by this paper
• High density synthetic oligonucleotide arrays

  1999cited by this paper
• Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.

  1999cited by this paper
• Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation.

  1999cited by this paper
• Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia.

  1999cited by this paper
• Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates.

  1999cited by this paper
• Biology and treatment of childhood T-lineage acute lymphoblastic leukemia.

  1998cited by this paper
• P‐glycoprotein‐mediated methotrexate resistance in CCRF‐CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene

  1998cited by this paper
• Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy.

  1998cited by this paper
• Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study.

  1998cited by this paper
• Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression.

  1997cited by this paper
• Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity.

  1997cited by this paper
• Overexpression of p21waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells.

  1997cited by this paper
• Intrinsic and acquired resistance to methotrexate in acute leukemia.

  1996cited by this paper
• Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.

  1996cited by this paper
• Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.

  1994cited by this paper
• Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia.

  1994cited by this paper
• Patient characteristics associated with high-risk methotrexate concentrations and toxicity.

  1994cited by this paper
• Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia.

  1992cited by this paper
• Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study.

  1992cited by this paper
• Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments.

  1990cited by this paper
• Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study.

  1990cited by this paper
• Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19).

  1990cited by this paper
• Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates.

  1985cited by this paper
• Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate.

  1985cited by this paper
• Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates.

  1985cited by this paper
• The pharmacology and clinical use of methotrexate.

  1983cited by this paper
• Enzymatic synthesis and function of folylpolyglutamates

  1981cited by this paper

• Therapeutic drug monitoring in acute lymphoblastic leukemia–a deep dive into pharmacokinetics, -dynamics, and -genetics of antileukemic drugs

  2025cites this paper
• Methotrexate resistance and its regulatory mechanisms in pediatric tumors and beyond.

  2025cites this paper
• After 75 Years of Methotrexate, Can Treatment Results Be Improved With Appropriate Folinic Acid Rescue?

  2025cites this paper
• Methotrexate polyglutamates

  2024cites this paper
• Detailed resume of S-methyltransferases: Categories, structures, biological functions and research advancements in related pathophysiology and pharmacotherapy.

  2024cites this paper
• The advances of E2A-PBX1 fusion in B-cell acute lymphoblastic Leukaemia

  2023cites this paper
• Novel and replicated clinical and genetic risk factors for toxicity from high‐dose methotrexate in pediatric acute lymphoblastic leukemia

  2023cites this paper
• The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia

  2023cites this paper
• Glutathione levels are associated with methotrexate resistance in acute lymphoblastic leukemia cell lines

  2022cites this paper
• Hyperdiploidy: the longest known, most prevalent, and most enigmatic form of acute lymphoblastic leukemia in children

  2022cites this paper
• Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia

  2021cites this paper
• EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism

  2020cites this paper
• HSH2D contributes to methotrexate resistance in human T-cell acute lymphoblastic leukaemia

  2020cites this paper
• Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo.

  2020cites this paper
• The Role of ARID5B in Acute Lymphoblastic Leukemia and Beyond

  2020cites this paper
• Identification of cell cycle dependent methotrexate resistance in placenta site trophoblastic tumors

  2020cites this paper
• Chapter 2 Identifying Targets for New Therapies in Children with Acute Lymphoblastic Leukemia

  2019cites this paper
• Association of transcriptional levels of folate-mediated one-carbon metabolism-related genes in cancer cell lines with drug treatment response.

  2019cites this paper
• Glutamic Acid Increased Methotrexate Polyglutamation and Cytotoxicity in a CCRF-SB Acute Lymphoblastic Leukemia Cell Line

  2019cites this paper
• Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment

  2019influential citation
• DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide.

  2019cites this paper
• Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know?

  2019cites this paper
• Genomics and pharmacogenomics of pediatric acute lymphoblastic leukemia.

  2018cites this paper
• Chapter 2 Acute Lymphoblastic Leukemia

  2017cites this paper
• Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Antileukemic Drugs

  2017cites this paper
• Folylpoly-γ-glutamate synthetase: A key determinant of folate homeostasis and antifolate resistance in cancer.

  2016cites this paper
• 17. Genetic variants of folate metabolic pathways in hematological toxicity of leukemia patients

  2016cites this paper
• Influx transporter variants as predictors of cancer chemotherapy-induced toxicity: systematic review and meta-analysis.

  2016cites this paper
• Pharmacogenetic Testing for Methotrexate Treatment in Leukemia Patients

  2016cites this paper
• The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma

  2015cites this paper
• Cell lines and animal model in the analysis of pharmacogenomics markers in childhood acute lymphoblastic leukemia

  2015cites this paper
• Altered Metabolism in Down Syndrome

  2015cites this paper
• Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia

  2015influential citation
• Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.

  2015cites this paper
• Uncovering Differential Multi-microRNA Signatures of Acute Myeloid and Lymphoblastic Leukemias with a Machine-Learning-Based Network Approach

  2014cites this paper
• Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia: Clinical Facts and Fiction

  2014cites this paper
• Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.

  2014cites this paper
• Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia

  2014cites this paper
• High-Dose Cyclophosphamide for the Treatment of Refractory T-Cell Acute Lymphoblastic Leukemia in Children

  2014cites this paper
• Current approaches for TYMS polymorphisms and their importance in molecular epidemiology and pharmacogenetics.

  2013cites this paper
• FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia

  2013cites this paper
• Flow cytometric chemosensitivity assay using JC-1, a sensor of mitochondrial transmembrane potential, in acute leukemia

  2013cites this paper
• A Health‐Care System Perspective on Implementing Genomic Medicine: Pediatric Acute Lymphoblastic Leukemia as a Paradigm

  2013cites this paper
• Mathematical modeling of folate metabolism

  2013cites this paper
• T-Cell Malignancies in Children and Adolescents: State of the Clinical and Biological Science

  2013cites this paper
• Gene-expression signatures differ between different clinical forms of familial hemophagocytic lymphohistiocytosis.

  2013cites this paper
• Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia

  2013cites this paper
• Targeted expression of human folylpolyglutamate synthase for selective enhancement of methotrexate chemotherapy in osteosarcoma cells

  2013cites this paper
• 5 S-Adenosylmethionine : A Novel Factor in the Individualization of Thiopurine Therapy

  2012cites this paper
• The Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Risk Stratification and Strategies

  2012cites this paper
• [The mbr-FPGS efficient expression plasmid enhances the sensitivity of Jurkat cells to methotrexate].

  2012influential citation
• Intracellular disposition of methotrexate in acute lymphoblastic leukemia in children.

  2012cites this paper
• Investigation of the molecular response to folate metabolism inhibition.

  2012influential citation
• Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in china with or without specific fusion transcripts: A single institutional study of 1,004 patients

  2012cites this paper
• Red blood cell folate concentrations and polyglutamate distribution in juvenile arthritis: predictors of folate variability

  2012cites this paper
• [T-cell pediatric acute lymphoblastic leukemia: analysis of survival and prognostic factors in 4 consecutive protocols of the Spanish cooperative study group SHOP].

  2012cites this paper
• Çocukluk Çaği Akut Lenfoblastik Lösemisi

  2012cites this paper
• S-Adenosylmethionine: A Novel Factor in the Individualization of Thiopurine Therapy

  2012cites this paper
• Molecular Techniques Used in the Evaluation of Pediatric Acute Leukemia

  2012cites this paper
• Recent Developments in the Management of T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma

  2012cites this paper
• Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.

  2011influential citation
• Polymorphisms in folate-related genes: impact on risk of adult acute lymphoblastic leukemia rather than pediatric in Han Chinese

  2011cites this paper
• Identifying Targets for New Therapies in Children with Acute Lymphoblastic Leukemia

  2011cites this paper
• PharmGKB summary: methotrexate pathway.

  2011cites this paper
• Molecular Diagnostics, Targeted Therapy, and the Indication for Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia

  2011cites this paper
• Reply to B.A. Kamen et al

  2011cites this paper
• The Need for New Agents

  2011cites this paper
• T-Cell Acute Lymphoblastic Leukemia

  2011cites this paper
• Classification and Treatment of Acute Lymphoblastic Leukemia

  2011cites this paper
• Determinants of antifolate and 5-fluorouracil efficacy

  2011cites this paper
• Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico.

  2010cites this paper
• Improved prognosis for older adolescents with acute lymphoblastic leukemia.

  2010cites this paper
• Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy

  2010cites this paper
• Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia

  2010cites this paper
• Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside?

  2010cites this paper
• Old drug--new insights--better treatment?

  2010cites this paper
• Modeling Mechanisms of In Vivo Variability in Methotrexate Accumulation and Folate Pathway Inhibition in Acute Lymphoblastic Leukemia Cells

  2010cites this paper
• Pharmacogenomics in pediatric leukemia

  2010cites this paper
• Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia.

  2010influential citation
• SLC19A1 pharmacogenomics summary

  2010cites this paper
• Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma

  2009cites this paper
• High hyperdiploid childhood acute lymphoblastic leukemia

  2009cites this paper
• Functionally Overlapping Roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the Elimination of Methotrexate and Its Main Toxic Metabolite 7-Hydroxymethotrexate In vivo

  2009cites this paper
• Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia.

  2009cites this paper
• Expression and alternative splicing of folate pathway genes in HapMap lymphoblastoid cell lines.

  2009cites this paper
• Germline genomic variants associated with childhood acute lymphoblastic leukemia

  2009cites this paper
• Pharmacogenetics in acute lymphoblastic leukemia.

  2009cites this paper
• 5,10-Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL).

  2009cites this paper
• Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival

  2009cites this paper
• Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia.

  2009cites this paper
• Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis.

  2009cites this paper
• Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm of childhood acute lymphoblastic leukemia.

  2009cites this paper
• Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.

  2009cites this paper
• Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: associations with clinical outcome in childhood acute lymphoblastic leukemia

  2009cites this paper
• Treating childhood acute lymphoblastic leukemia without cranial irradiation.

  2009cites this paper
• Advances in individual prediction of methotrexate toxicity: a review

  2009cites this paper
• Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia.

  2009cites this paper
• Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.

  2009cites this paper
• Risk-adapted treatment of pediatric acute lymphoblastic leukemia.

  2009cites this paper
• High-dose methotrexate: the rationale...

  2009cites this paper